


MedGenome strengthens presence in infectious disease testing

22 May 2020 | News

The partnership with Iravatham's lab will help integrate MedGenome's flagship innovation SPIT-SEQ, with various tests offered by Dr. Iravatham for Tuberculosis



MedGenome Labs Ltd collaborates with Dr Iravatham's clinical laboratory at Hyderabad to enhance the Tuberculosis diagnostics offering and gets ICMR approval for RT-PCR testing for COVID-19 with its current partner Xcyton Diagnostics

One of the biggest problems that Indian has faced in the field of Healthcare is in the area of infectious diseases. Before COVID-19 was recognised as a global pandemic, India was at the centre of the discussion on reducing global tuberculosis burden. With an immensely high prevalence of tuberculosis in India, the world is looking towards India to control the same. Indian government has set a deadline of ending TB by 2025. While India is one of the highest contributor to the global TB burden, the same nation, on the other hand, is looked upon as a proactive decision maker as far as controlling COVID-19 spread is concerned.

However, There are reports that show how the COVID-19 lockdown is taking us back to 2013 as far as our fight against TB is concerned. The lockdown may aggravate the existing TB burden as more TB patients may go undiagnosed and hence untreated.

With both these public health issues in focus, MedGenome Labs, India's biggest genetic diagnostics lab collaborates with Dr. Iravatham's clinical laboratory in Hyderabad, a niche testing lab in the field of Tuberculosis diagnostics strengthening its presence in infectious diseases testing. MedGenome's partner Xcyton Diagnostics is also awarded the ICMR approval to undertake COVID-19 testing at its lab in Bengaluru.

Citing their strengths, Dr. Vedam Ramprasad, CEO, MedGenome Labs, said "Our collaboration with Dr. Iravatham's lab is a milestone in TB testing ecosystem and we are committed to take more steps to integrate SPIT SEQ, our proprietary whole

genome sequencing based test for diagnosis and drug resistance detection directly from sputum samples, into TB testing ecosystem”.

The partnership with Iravatham’s lab will help integrate MedGenome’s flagship innovation SPIT-SEQ, with various tests offered by Dr. Iravatham for Tuberculosis and also set up a state of the art BSL2/3 infectious testing lab in Hyderabad “With India in the limelight as far as global TB burden is concerned, diagnosis and drug resistance detection take the centre stage. Offering a complete range of tests, right from smear microscopy to a sequencing-based test, will help shorten the time to diagnose, and lead to timely intervention.”, said, Dr Chitra Iravatham, Dr Iravatham& Clinical Laboratory (DICL)

Dr BV Ravikumar, Founder and Managing Director, XCyton Diagnostics Ltd said, “We are equipped to undertake a minimum of 1000 tests per day, with an ability to scale up the capacity manifolds in a matter of a few days. We are strongly looking at making an impact and help India fight COVID-19”.

MedGenome is the current market leader in this industry?to have studied genetic disposition in multiple therapy areas like Cancer, Reproductive Health, TB, Rare Diseases amongst others in the country. Currently, the tests by MedGenome are recommended by over 1600 hospital networks and clinics in India.